Identity
- Trade Name
- Ki-67 IHC MIB-1 pharmDx (Dako Omnis) FDA UDI
- Generic Name
- Ki67 antigen IVD, kit, enzyme immunohistochemistry FDA UDI
- Device Name
- Ki-67 IHC MIB-1 pharmDx (Dako Omnis) FDA UDI
- Model / Reference
- GE020 FDA UDI
- Description
- Ki-67 IHC MIB-1 pharmDx (Dako Omnis) FDA UDI
Identifiers
- Primary DI / UDI-DI
- 05700573004591 FDA UDI
- PMA Number
- P210026 FDA UDI
- FDA Product Code
- QQT FDA UDI
- GMDN Term
- Ki67 antigen IVD, kit, enzyme immunohistochemistry FDA UDI
Classification
- Device Class
- Class III FDA UDI
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
No
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
Yes
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
No
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Ki67 antigen IVD, kit, enzyme immunohistochemistry
Ki-67 IHC MIB-1 pharmDx (Dako Omnis) by Agilent Technologies Inc. — Class III — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Ki67 antigen IVD, kit, enzyme immunohistochemistry.
- Q-STAIN® QSX-Enh-P Ki67 — NOVODIAX, INC. · Class I
- ihcDirect® Ki67 Ab Conjugate 5mL — NOVODIAX, INC. · Class I
- CINtec PLUS Cytology — Ventana Medical Systems
- Q-STAIN® QSX-Enh-F Ki67 — NOVODIAX, INC. · Class I
- ihcDirect® Ki67Ab Conjugate 15mL — NOVODIAX, INC. · Class I
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | Class III | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Agilent Technologies Inc.
Sources (1)
- FDA UDI cf67f102-7090-4bc1-8352-8bb8791f5843 37 fields · synced May 30, 2026